Prognostic utility of HOXB13:IL17BR and molecular grade index in early-stage breast cancer patients from the Stockholm trial.
Prognostic utility of HOXB13:IL17BR and molecular grade index in early-stage breast cancer patients from the Stockholm trial.
复制标题
DOI：
10.1038/bjc.2011.145
复制
发表时间：
2011-05-24
影响因子：
8.8
通讯作者：
Stal, O.
中科院分区：
文献类型：
--
作者：
Jerevall, P-L;Ma, X-J;Li, H.;Salunga, R.;Kesty, N. C.;Erlander, M. G.;Sgroi, D. C.;Holmlund, B.;Skoog, L.;Fornander, T.;Nordenskjold, B.;Stal, O.
开发了结合两种基因表达测定 HOXB13 : IL17BR (H : I) 和分子分级指数 (MGI) 的二分指数来评估乳腺癌患者的复发风险。该研究的目的是证明联合指数在早期乳腺癌中的预后效用。在对来自随机前瞻性斯德哥尔摩试验的 588 名 ER 阳性他莫昔芬治疗和未治疗乳腺癌患者进行的盲法回顾性分析中，使用实时 RT-PCR 测量了 H : I 和 MGI。通过 Kaplan-Meier 分析和 Cox 比例风险回归评估与患者结果的关联。使用 Cox 模型开发了连续风险指数。二分 H : I+MGI 与远处复发和乳腺癌死亡显着相关。 >50% 的他莫昔芬治疗患者被归类为低风险，其 10 年远处复发风险 <3%。他莫昔芬治疗组开发了连续风险模型（乳腺癌指数 (BCI)），未治疗组的预后表现测试显示，53% 的患者被归类为低风险，10 年远处复发风险为 8.3%。该随机前瞻性试验队列的回顾性分析验证了 H : I+MGI 的预后效用，并用于开发和测试连续风险模型，该模型能够预测患者水平的远处复发风险。
A dichotomous index combining two gene expression assays, HOXB13 : IL17BR (H : I) and molecular grade index (MGI), was developed to assess risk of recurrence in breast cancer patients. The study objective was to demonstrate the prognostic utility of the combined index in early-stage breast cancer. In a blinded retrospective analysis of 588 ER-positive tamoxifen-treated and untreated breast cancer patients from the randomised prospective Stockholm trial, H : I and MGI were measured using real-time RT–PCR. Association with patient outcome was evaluated by Kaplan–Meier analysis and Cox proportional hazard regression. A continuous risk index was developed using Cox modelling. The dichotomous H : I+MGI was significantly associated with distant recurrence and breast cancer death. The >50% of tamoxifen-treated patients categorised as low-risk had <3% 10-year distant recurrence risk. A continuous risk model (Breast Cancer Index (BCI)) was developed with the tamoxifen-treated group and the prognostic performance tested in the untreated group was 53% of patients categorised as low risk with an 8.3% 10-year distant recurrence risk. Retrospective analysis of this randomised, prospective trial cohort validated the prognostic utility of H : I+MGI and was used to develop and test a continuous risk model that enables prediction of distant recurrence risk at the patient level.
登录
查看更多内容
影响因子：
45.3
作者：
Ravdin, PM;Siminoff, LA;Parker, HL
通讯作者：
Parker, HL
影响因子：
3.8
作者：
Jerevall, Piiha-Lotta;Brommesson, Sara;Stal, Olle
通讯作者：
Stal, Olle
影响因子：
158.5
作者：
van de Vijver, MJ;He, YD;Bernards, R
通讯作者：
Bernards, R
影响因子：
2.9
作者：
WRANGE, O;NORDENSKJOLD, B;GUSTAFSSON, JA
通讯作者：
GUSTAFSSON, JA
影响因子：
45.3
作者：
Ma, Xiao-Jun;Hilsenbeck, Susan G.;Erlander, Mark G.
通讯作者：
Erlander, Mark G.